Reply to the comment by Cipolla et al. on: inhaled antimicrobial therapy--barriers to effective treatment, by J. Weers, Adv. Drug Deliv. Rev. (2015), http://dx.doi.org/10.1016/j.addr.2014.08.013.
Novartis Pharmaceuticals Corporation, 150 Industrial Road, San Carlos, CA, USA. Electronic address: jeff.weers@novartis.com.
Jeffry
J
Weers
D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D016503:Drug Delivery Systems / Q000379:methods*; D024901:Drug Resistance, Multiple, Bacterial; D006801:Humans; D012141:Respiratory Tract Infections / Q000188:drug therapy*
D000900:Anti-Bacterial Agents